Related Experiment Videos
Development of daptomycin for gram-positive infections
1Cubist Pharmaceuticals, Inc., 24 Emily Street, Cambridge, MA 02139, USA. ftally@cubist.com
The Journal of Antimicrobial Chemotherapy
|October 6, 2000
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Daptomycin: a novel agent for Gram-positive infections.
Expert opinion on investigational drugs·2005
A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-alpha.
The American journal of gastroenterology·2001
Once-daily dosing in dogs optimizes daptomycin safety.
Antimicrobial agents and chemotherapy·2000
Drug target validation: lethal infection blocked by inducible peptide.
Proceedings of the National Academy of Sciences of the United States of America·2000
Antimicrobial resistance in anaerobes.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1997
Characterization of the intrinsic AmpC β-lactamase of Escherichia marmotae and its impact on decreased susceptibility to cefiderocol and resistance to broad-spectrum cephalosporins.
The Journal of antimicrobial chemotherapy·2026
Epidemiology of KPC-producing Enterobacterales isolated from 2019 to 2023 in France.
The Journal of antimicrobial chemotherapy·2026
Inter- and intraindividual variability of long-acting injectable cabotegravir/rilpivirine trough concentrations after 1 year of continuous use.
The Journal of antimicrobial chemotherapy·2026
Differential salivary disposition of linezolid and its two major metabolites (PNU-142300 and PNU-142586) after a single dose in healthy adults.
The Journal of antimicrobial chemotherapy·2026
Synergy between orally bioavailable antibiotics and dalbavancin against MRSA.
The Journal of antimicrobial chemotherapy·2026